Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169429 | 0.85 | HPGD (0.59) | HPGDMAPTTP53 | |
| SCHEMBL7833153 | 0.84 | HPGD (0.70) | HPGD | |
| SCHEMBL12501015 | 0.82 | MEN1 (0.49) | MEN1KMT2AHPGDCMA1DAO | |
| SCHEMBL7840035 | 0.82 | MEN1 (0.71) | MEN1KMT2AHPGDCMA1DAO | |
| SCHEMBL4176930 | 0.82 | TYMP (0.48) | TYMPMEN1KMT2AHPGDDAO | |
| SCHEMBL4172709 | 0.81 | HPGD (0.67) | TYMPMEN1KMT2AHPGDDAO | |
| SCHEMBL7830417 | 0.79 | L3MBTL1 (0.64) | MEN1KMT2AHPGDCMA1DAO | |
| SCHEMBL4172004 | 0.78 | HPGD (0.44) | MEN1KMT2AHPGDDAO | |
| SCHEMBL12410767 | 0.78 | MMP13 (0.50) | MEN1KMT2AHPGDCMA1DAO | |
| SCHEMBL17243375 | 0.78 | MMP13 (0.50) | MEN1KMT2AHPGDCMA1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| WO-2010147969-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147975-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147973-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TYMP 702/4885MEN1 3454/4885KMT2A 3709/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TYMP 702/4885MEN1 3454/4885KMT2A 3709/4885 |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TYMP 697/4885MEN1 3513/4885KMT2A 3849/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TYMP 704/4885MEN1 3509/4885KMT2A 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.